EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Beta‐hydroxy‐beta‐methylbutyrate supplementation and functional outcomes in multitrauma patients: A pilot randomized controlled trial

Kym Wittholz iD, Kate Fetterplace iD, Amalia Karahalios, Yasmine Ali Abdelhamid iD, Lisa Beach, David Read, René Koopman, Jeffrey J Presneill, Adam M Deane iD

Journal of Parenteral and Enteral Nutrition · 2023

DOI: 10.1002/jpen.2527 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Parenteral and Enteral Nutrition, 2023. Verfasst von Kym Wittholz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allied Health (Clinical Nutrition), The Royal Melbourne Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Muscle, Skeletal, Valerates. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: This project is supported by the Mary Elizabeth Watson Early Career Research Fellowship provided by the Melbourne Health foundation, which provides $30,000 per….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Beta‐hydroxy‐beta‐methylbutyrate (HMB) is a nutrition supplement that may attenuate muscle wasting from critical illness. This trial aimed to determine feasibility of administering a blinded nutrition supplement in the intensive care unit (ICU) and continuing it after ICU discharge.

Methods

Single‐center, parallel‐group, blinded, placebo‐controlled, randomized feasibility trial. After traumatic injury necessitating admission to ICU, participants were randomized to receive an enteral study supplement of 3 g of HMB (intervention) or placebo daily for 28 days or until hospital discharge. Primary outcome was feasibility of administering the study supplement, quantified as protocol adherence. Secondary outcomes included change in quadriceps muscle thickness, measured weekly until day 28 or hospital discharge by using ultrasound and analyzed by using a linear mixed model.

Results

Fifty randomized participants (intervention, n = 26; placebo, n = 24) showed comparable baseline characteristics. Participants received 862 (84.3%) of the 1022 prescribed supplements during hospitalization with 543 (62.8%) delivered via an enteral feeding tube. The median (IQR) number of study supplements successfully administered per participant was 19.5 (13.0–24.0) in the intervention group and 16.5 (8.5–23.5) in the placebo group. Marked loss of quadriceps muscle thickness occurred in both groups, with the point estimate favoring attenuated muscle loss with the intervention, albeit with wide CIs (mean intervention difference after 28 days, 0.26 cm [95% CI, −0.13 to 0.64]).

Conclusion

A blinded, placebo‐controlled, randomized clinical trial of daily enteral HMB supplementation for up to 28 days in hospital is feasible. Any effect of HMB supplementation to attenuate muscle wasting after traumatic injury remains uncertain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle, SkeletalValeratesHumansPilot ProjectsDietary SupplementsMuscular Atrophy

Stichwörter der Autor:innen

beta-hydroxy-beta-methylbutyratecritical illnessenteral nutritionmuscle massnutrition therapy

Substanzen

beta-hydroxyisovaleric acidValerates

Autor:innen und Institutionen

  • Department of Allied Health (Clinical Nutrition), The Royal Melbourne Hospital, Melbourne, Australia.
  • Department of Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, Australia.
  • Center of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
  • Department of Intensive Care, The Royal Melbourne Hospital, Melbourne, Australia.
  • Department of Allied Health (Physiotherapy), The Royal Melbourne Hospital, Melbourne, Australia.
  • Department of Trauma and General Surgery, The Royal Melbourne Hospital, Melbourne, Australia.

ORCID-Profile: Kym Wittholz, Kate Fetterplace, Yasmine Ali Abdelhamid, Adam M Deane

Förderung

  • This project is supported by the Mary Elizabeth Watson Early Career Research Fellowship provided by the Melbourne Health foundation, which provides $30,000 per…

Zitieren

APA

Wittholz, K., Fetterplace, K., Karahalios, A., Ali Abdelhamid, Y., Beach, L., Read, D., Koopman, R., Presneill, J. J., & Deane, A. M. (2023). Beta‐hydroxy‐beta‐methylbutyrate supplementation and functional outcomes in multitrauma patients: A pilot randomized controlled trial. Journal of Parenteral and Enteral Nutrition. https://doi.org/10.1002/jpen.2527

Vancouver

Wittholz K, Fetterplace K, Karahalios A, Ali Abdelhamid Y, Beach L, Read D, et al. Beta‐hydroxy‐beta‐methylbutyrate supplementation and functional outcomes in multitrauma patients: A pilot randomized controlled trial. Journal of Parenteral and Enteral Nutrition. 2023. doi:10.1002/jpen.2527

BibTeX
@article{Wittholz2023,
  author = {Wittholz, Kym and Fetterplace, Kate and Karahalios, Amalia and Ali Abdelhamid, Yasmine and Beach, Lisa and Read, David and Koopman, René and Presneill, Jeffrey J and Deane, Adam M},
  title = {Beta‐hydroxy‐beta‐methylbutyrate supplementation and functional outcomes in multitrauma patients: A pilot randomized controlled trial},
  journal = {Journal of Parenteral and Enteral Nutrition},
  year = {2023},
  doi = {10.1002/jpen.2527}
}
Kostenlos starten →